招商证券国际发表报告指，康哲药业(00867.HK) 消化集采影响，由中国最大CSO(合同销售组织)向Pharma(制药)转型，并迈向全链条发展创新药企。预计2025年至2027年净利润分别为16.5亿、19.6亿及22.7亿元人民币，按年增长1.5%、18.9%及15.8%，首次覆盖给予“强烈推荐”评级。从业绩端看，随着2023年三大核心产品陆续纳入集采，公司短期业绩有所波动，但2024年起创新...
Source Link招商证券国际发表报告指，康哲药业(00867.HK) 消化集采影响，由中国最大CSO(合同销售组织)向Pharma(制药)转型，并迈向全链条发展创新药企。预计2025年至2027年净利润分别为16.5亿、19.6亿及22.7亿元人民币，按年增长1.5%、18.9%及15.8%，首次覆盖给予“强烈推荐”评级。从业绩端看，随着2023年三大核心产品陆续纳入集采，公司短期业绩有所波动，但2024年起创新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.